Mutants of plant genes for developing cancer vaccines

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 147-155

  Massa, Silvia ^a   Paolini, Francesca ^b   Spanò, Laura ^c   Franconi, Rosella ^a   Venuti, Aldo ^b  

^a ENEA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

DNA vaccines; E7 protein; HPV; Ribosome inactivating proteins; Saporin; Tumor immunity

Indexed keywords

CANCER VACCINE; DNA VACCINE; IMMUNOGLOBULIN G; PROTEIN E7; SAPORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DNA IMMUNIZATION; EMBRYO; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; MOUSE; NONHUMAN; PLANT GENE; REVIEW; UTERINE CERVIX CANCER; VERRUCA VULGARIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; PLANTS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; RODENT DISEASES;

EID: 84855722329     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14577     Document Type: Review

References (41)

1. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Ann Rev Immunol 2000; 18:927-74. (Pubitemid 30365401)
2. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci USA 2004; 101:14646-52. (Pubitemid 39346737)
3. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20:7888-98. (Pubitemid 33135315)
4. Su JH, Wu A, Scotney E, Ma B, Monie A, Hung CF, et al. Immunotherapy for Cervical Cancer: Research Status and Clinical Potential. BioDrugs 2010; 24:109-29.
5. Ma B, Roden R, Wu TC. Current Status of HPV Vaccines. J Formos Med Assoc 2010; 109:481-3.
6. Eisai. A Study of Amolimogene (ZYC101a) in Patients with High Grade Cervical Intraepithelial Lesions of the Uterine Cervix 2009 (Available from: http://clinicaltrials. gov/ct2/show/NCT00264732).
7. O'Brien PM, Campo MS. Papillomaviruses: a correlation between immune evasion and oncogenicity? Trends Microbiol 2003; 11:300-5. (Pubitemid 37289035)
8. Cheng YW, Lee H, Shiau MY, Wu TC, Huang TT, Chang YH. Human papillomavirus type 16/18 upregulates the expression of interleukin-6 and antiapoptotic Mcl-1 in non-small cell lung cancer. Clin Cancer Res 2008; 1:4705-12.
9. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 2004; 11:1011-8. (Pubitemid 38923625)
10. Vaccine therapy with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia. (Available from: http://clinicaltrials. gov/ct2/show/NCT00788164).
11. Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R. Anti-tumor activity of DNA vaccines based on the Human Papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther 2008; 19:354-64. (Pubitemid 351591427)
12. Gerloni M, Xiong S, Mukerjee S, Schoenberger SP, Croft M, Zanetti M. Functional cooperation between T-helper cell determinants. Proc Natl Acad Sci USA 2002; 97:13269-74.
13. Savelyeva N, Zhu D, Stevenson FK. Engineering DNA vaccines that include plant virus coat proteins. Biotechnol Genet Eng Rev 2003; 20:101-14. (Pubitemid 38222341)
14. Hartley MR, Lord JM. Cytotoxic ribosome-inactivating lectins from plants. Biochim Biophys Acta 2004; 1701:1-14.
15. Stirpe F. Ribosome inactivating proteins. Toxicon 2004; 44:371-83.
16. Ng TB, Wong JH, Wang H. Recent progress in research on ribosome inactivating proteins. Curr Prot Pept Sci 2010; 11:37-53.
17. Cheung LH, Marks JW, Rosenblum M. Development of 'designer toxins' with reduced antigenicity and size. Proc Am Assoc Cancer Res 2004; 45:874-5.
18. Zarovni N, Vago R, Fabbrini MS. Saporin suicide gene therapy. Methods Mol Biol 2009; 542:261-83.
19. Stirpe F, Battelli MG. Ribosome-inactivating proteins: progress and problems. Cell Mol Life Sci 2006; 63:1850-66.
20. Castelletti D, Fracasso G, Righetti S, Tridente G, Schnell R, Engert A, et al. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol 2004; 136:365-72. (Pubitemid 38543458)
21. Frankel AE. Reducing the Immune Response to Immunotoxin, Clin Cancer Res 2004; 10:13-5. (Pubitemid 38114155)
22. Hajto T, Hostanska K, Weber K, Zinke H, Fischer J, Mengs U, et al. Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo. Nat Immun 1998; 16:34-46. (Pubitemid 28499445)
23. Bhutia SK, Mallick SK, Maiti TK. In vitro immuno-stimulatory properties of Abrus lectins derived peptides in tumor-bearing mice. Phytomedicine 2009; 16:776-82.
24. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ. Increased secretion of tumor necrosis factors alpha, interleukin 1 and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 1990; 50:3322-6. (Pubitemid 20190139)
25. Zhao J, Ben LH, Wu YL, Hu W, Ling K, Xin SM, et al. Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors. J Exp Med 1999; 190:101-11. (Pubitemid 29330127)
26. Li M, Chen Y, Liu Z, Shen F, Bian X, Meng Y. Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Biochim Biophys Sin 2009; 792-9.
27. Sikriwal D, Ghosh P, Batra JK. Ribosome inactivating protein saporin induces apoptosis through mitochondrial cascade, independent of translation inhibition. Intl J Biochem & Cell Biol 2008; 40:2880-8.
28. Ferreras JM, Barbieri L, Girbes T, Battelli MG, Rojo MA, Arias FJ, et al. Distribution and properties of major ribosome inactivating proteins (28S rRNA N- glycosidases) of the plant Saponaria officinalis L. (Caryophyllaceae) Biochim Biophys Acta 1993; 1216:31-42. (Pubitemid 23314497)
29. Santanchè S, Bellelli A, Brunori M. The unusual stability of saporin, a candidate for the synthesis of immunotoxins. Biochem Biophys Res Commun 1997; 234:129-32. (Pubitemid 27267546)
30. Bergamaschi G, Perfetti V, Tonon L, Novella A, Lucotti C, Danova M, et al. Saporin, a ribosomeinactivating protein used to prepare immunotoxins, induces cell death via apoptosis. British J Haematol 1996; 93:789-94. (Pubitemid 26199319)
31. Dunn LA, Evander M, Tindle RW, Bulloch AL, de Kluyver RL, Fernando GJ, et al. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 1997; 235:94-103. (Pubitemid 27380809)
32. Massa S, Franconi R, Brandi R, Muller A, Mett V, Yusibov V, et al. Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 2007; 25:3018-21. (Pubitemid 46505044)
33. Pardoll DM. Cancer vaccines. Nat Med 1998; 4:525-31. (Pubitemid 28228086)
34. Tan BKH, Vanitha J. Immunomodulatory and Antimicrobial Effects of Some Traditional Chinese Medicinal Herbs: A Review. Curr Med Chem 2004; 11:1423-30. (Pubitemid 38735787)
35. Franconi R, Spanò L, Venuti A, Massa S. Italian Patent RM2009A000383 and International application No. PCT/IT2010/000324 'Vaccines based on genetic chimera of viral and/or tumoral antigens and plant proteins'.
36. Marshall RS, D'Avila F, Di Cola A, Traini R, Solinas M, Spanò L, et al. Signal peptide regulated toxicity of a plant ribosome-inactivating protein during cell stress. Plant J 2010; In press.
37. Pittaluga E, Poma A, Tucci A, Spanò L. Expression and characterisation in E. coli of mutant forms of saporin. J Biotechnology 2005; 117:263-6. (Pubitemid 40615569)
38. Bonini F, Traini R, Comper F, Fracasso G, Tomazzolli R, Dalla Serra M, et al. N-terminal deletion affects catalytic activity of saporin toxin. J Cell Biochem 2006; 98:1130-9. (Pubitemid 44128355)
39. Venuti A, Massa S, Mett V, Dalla Vedova L, Paolini F, Franconi R, et al. An E7-Based Therapeutic Vaccine Protects Mice against HPV16 Associated Cancer. Vaccine 2009; 27:3395-7.
40. Tartarini A, Pittaluga E, Marcozzi G, Testone G, Rodrigues-Pousada RA, Giannino D, et al. Differential expression of saporin genes upon wounding, ABA treatment and leaf development. Physiol Plant 2010; 140:141-52.
41. + T cells using an ELISPOT assay. J Immunol Met 1995; 181:45-54.